Current possibilities for nebulizer therapy
https://doi.org/10.21518/2079-701X-2019-15-106-111
Abstract
This article discusses the main aspects of the nebulizer therapy used to treat respiratory diseases. The basic principle of operation of all types of nebulizers is based on the generation of aerosol containing particles comprising an active substance. Currently, there are three types of nebulizers: jet, or compressor (which uses the energy of a gas jet), ultrasonic (which uses oscillation energy of the piezoelectric element) and membrane (Mesh nebulizers). The jet nebulizers are the most common, because they have affordable cost, are easy to use, however, using this type of nebulizers is accompanied by quite large losses of the drug (more than 50%), and they are quite noisy due to the compressor. Among the advantages of ultrasonic nebulizers are virtually silent operation, fast aerosol production and shorter inhalation times compared to compressor devices, small size and weight, and operation from the batteries. However, one of the most important disadvantages of ultrasonic nebulizers is the limited range of drugs that can be used for inhalation, which significantly limits their use in pulmonological practice. In particular, they are not suitable for inhalation of suspensions (glucocorticosteroids) due to the impossibility of homogeneous nebulization, in addition, part of the GCS molecules are destroyed by ultrasound. In recent years, the greatest prospects have been associated with the use of a new generation of nebulizers created using the so-called Vibrating Mesh Technology. Membrane nebulizers have a number of advantages compared to the compressor and ultrasonic devices. Among them are a small residual volume, noiseless operation, high mobility due to the small size, weight and ability to operate using battery.
About the Authors
A. A. Zaytsev
Main Military Clinical Hospital Named after Academician N.N. Burdenko
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Professor, Chief Pulmonologist,
3, Gospitalnaya Pl., Moscow, 105229
M. A. Kharitonov
Military Medical Academy named after S.M. Kirov
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Professor, Chair for Therapy of Advanced Medical Education No. 1,
6, Akademika Lebedeva St., Saint Petersburg, 194044
V. A. Chernetsov
Main Military Clinical Hospital Named after Academician N.N. Burdenko
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Professor, Deputy Head,
3, Gospitalnaya Pl., Moscow, 105229
E. V. Kryukov
Main Military Clinical Hospital Named after Academician N.N. Burdenko
Russian Federation
Russian Federation
Corr. Member of RAS, Dr. of Sci. (Med.), Professor, Head,
3, Gospitalnaya Pl., Moscow, 105229
References
1. Global Initiative for Asthma 2019 (GINA). Available at: https://ginasthma.org/ginareports/
2. Chuchalin A.G., Avdeev S.N., Aysanov Z.R. et al. Bronchial asthma. Clinical guidelines; 2019. (In Russ.) Available at: http://spulmo.ru/upload/kr_bronhastma_2019.pdf.
3. Buist A.S., McBurnie M.A., Vollmer W.M., Gillespie S., Burney P., Mannino D.M., Menezes A.M., Sullivan S.D., Lee T.A., Weiss K.B., Jensen R.L., Marks G.B., Gulsvik A., NizankowskaMogilnicka E.; BOLD Collaborative Research Group.International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741-750. doi: 10.1016/S0140-6736(07)61377-4.
4. Menezes A.M., Perez-Padilla R., Jardim J.R., Muiño A., Lopez M.V., Valdivia G., Montes de Oca M., Talamo C., Hallal P.C., Victora C.G.; PLATINO Team. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005;366(9500):1875-1881. doi: 10.1016/S0140-6736(05)67632-5.
5. Chuchalin A.G., Khaltaev N., Antonov N.S., Galkin D.V., Manakov L.G., Antonini P., Murphy M., Solodovnikov A.G., Bousquet J., Pereira M.H., Demko I.V. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014;9:963-974. doi: 10.2147/COPD.S67283.
6. Avdeev S.N. Current possibilities for nebulizer therapy: operational principles and new technical solutions. RMZH =RMJ. 2013;(19):945- 952. (In Russ.) Available at: https://elibrary.ru/item.asp?id=20261261.
7. Zaitsev A.A., Kharitonov M.A. Modern methods of inhalation therapy of respiratory diseases. Voenno-meditsinskiy zhurnal = Military Medical Journal. 2015;(6):20-24. (In Russ.) Available at: https://elibrary.ru/item.asp?id=26341582.
8. Kutsenko M.A., Chuchalin A.G. Nebulizers and inhalation therapy in pulmonological practice. RMZH =RMJ. 2013;(29):1440-1445. (In Russ.) Available at: https://elibrary.ru/item.asp?id=21091048.
9. Bates D.V., Fish B.R., Hatch T.F., Mercer T.T., Morrow P.E. Deposition and retention models for internal dosimetry of the human respiratory tract. Task group on lung dynamics. Health Phys. 1966;12(2):173-207. Available at: https://www.ncbi.nlm.nih.gov/pubmed/5916786.
10. Boe J, Dennis JH, O’Driscoll BR, Bauer TT, Carone M, Dautzenberg B, Diot P, Heslop K, Lannefors L; European Respiratory Society Task Force on the use of nebulizers. European Respiratory Society Nebulizer Guidelines: Technical Aspects. Eur Respir J. 2001;18(1):228- 42. doi: 10.1183/09031936.01.00220001.
11. Dennis J. A review of issues relating to nebulizer standards. J Aerosol Med. 1998;11(Suppl 1):73-79. Available at: https://www.ncbi.nlm.nih.gov/pubmed/10180736.
12. Devadason S., Everald M., Linto J., Le Souef P. Comparison of drug delivery from conventional versus «Venturi» nebulizers. European Respiratory Journal. 1997;10(11):2479-2483 . doi: 10.1183/09031936.97.10112479.
13. Kendrick A., Smith E., Denyer J. Nebulisers–fill volume, residual volume and matching of nebuliser to compressor. Respir Med. 1995;89(3):157-159. doi: 10.1016/0954-6111(95)90241-4.
14. Swarbrick J., Boylan J. Ultrasonic nebulisers. In: Encyclopedia of Pharmaceutical Technology. New York: Marcel Dekker; 1997:339–351. Available at: https://gmpua.com/Process/EncyclopediaPT.pdf.
15. Nikander K., Turpeinen M., Wollmer P. The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J Aerosol Med. 1999;12(2):47-53. doi: 10.1089/jam.1999.12.47.
16. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care. 2002;47(12):1406- 1416; discussion 1416-8. Available at: https://www.ncbi.nlm.nih.gov/pubmed/12467499.
17. Vecellio L. The mesh nebulizer: a recent technical innovation for aerosol delivery. Breathe. 2006;2(3):253–260. Available at: https://breathe.ersjournals.com/content/ breathe/2/3/252.full.pdf.
18. Johnson J.C., Waldrep J.C., Guo J., Dhand R. Aerosol delivery of recombinant human DNAse I: in vitro comparison of a vibrating mesh nebulizer with a jet nebulizer. Respir Care. 2008;53:1703–1708. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19025706.
19. Fesenko O.V. Opportunities of modern mesh nebulizers use. Consilium medicum. 2018;20(11):52-54. (In Russ.) Available at: https://elibrary.ru/item.asp?id=36733385.
20. Sinopalnikov A.I., Zaitsev A.A. Patient Compliance with Antimicrobial Therapy of Lower Respiratory Tract Infections. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya Clinical Microbiology and Antimicrobial Chemotherapy. 2008;10(1):50-59. (In Russ.) Available at: http://www.antibiotic.ru/cmac/pdf/10_1_015.pdf.
21. Sinopal’nikov A.I., Zaytsev A.A. Modern view on the pharmacotherapy of exacerbations of chronic obstructive pulmonary disease. Lechashchiy vrach = Attending Physician. 2009;(10):45-49. (In Russ.) Available at: https://www.lvrach.ru/2009/10/10866825/
22. Kolosova N.G. Effectiveness of nebulizer therapy in children. RMZH = RMJ. 2015;(18):1086- 1090. (In Russ.) Available at: https://elibrary.ru/item.asp?id=25280832.
Review
For citations:
Zaytsev AA, Kharitonov MA, Chernetsov VA, Kryukov EV. Current possibilities for nebulizer therapy. Meditsinskiy sovet = Medical Council. 2019;(15):106-111. (In Russ.) https://doi.org/10.21518/2079-701X-2019-15-106-111
Views:
902
Email this article 